A blueprint for randomized trials targeting phosphorus metabolism in chronic kidney disease (Q37552700)

21 August 2017

1 reference

title

A blueprint for randomized trials targeting phosphorus metabolism in chronic kidney disease (English)

1 reference

21 August 2017

0 references

1

Tamara Isakova

1 reference

21 August 2017

3

Myles Wolf

1 reference

21 August 2017

Orlando M Gutiérrez

2

1 reference

PubMed ID

19606082

21 August 2017

language of work or name

English

0 references

publication date

15 July 2009

1 reference

21 August 2017

1 reference

21 August 2017

76

1 reference

21 August 2017

705-716

1 reference

21 August 2017

7

1 reference

https://scigraph.springernature.com/pub.10.1038/ki.2009.246

21 August 2017

0 references

cites work

Prevalence of chronic kidney disease in the United States

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Prevalence of CKD in the United States: a sensitivity analysis using the National Health and Nutrition Examination Survey (NHANES) 1999-2004.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Preventi

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

The epidemiology of chronic kidney disease stages 1 to 4 and cardiovascular disease: a high-risk combination

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Cardiovascular disease and subsequent kidney disease.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Kidney disease as a risk factor for recurrent cardiovascular disease and mortality

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the hypertension detection and follow-up program. The Hypertension Detection and Follow-up Program Cooperative Group

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Preventing microalbuminuria in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Normalization of hemoglobin level in patients with chronic kidney disease and anemia

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Effect of dialysis dose and membrane flux in maintenance hemodialysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

The Effects of Dietary Protein Restriction and Blood-Pressure Control on the Progression of Chronic Renal Disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Correction of anemia with epoetin alfa in chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Rosuvastatin and cardiovascular events in patients undergoing hemodialysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Inorganic phosphate induces apoptosis of osteoblast-like cells in culture

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Extracellular phosphate ions cause apoptosis of terminally differentiated epiphyseal chondrocytes.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Effect of phosphate, calcium and magnesium on bone resorption and hormonal responses in tissue culture

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Mineral metabolism, mortality, and morbidity in maintenance hemodialysis.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Serum phosphate levels and mortality risk among people with chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

High plasma phosphate as a risk factor for decline in renal function and mortality in pre-dialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Relationship of phosphorus and calcium-phosphorus product with mortality in CKD

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Relation between serum phosphate level and cardiovascular event rate in people with coronary disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Relations of Serum Phosphorus and Calcium Levels to the Incidence of Cardiovascular Disease in the Community

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Acute phosphate nephropathy following oral sodium phosphate bowel purgative: an underrecognized cause of chronic renal failure

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Calcium metabolism in uremic nephrocalcinosis: preventive effect of verapamil.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Increased nephron oxygen consumption: potential role in progression of chronic renal disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Renal toxicity of phosphate in rats

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Baseline predictors of renal disease progression in the African American Study of Hypertension and Kidney Disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Association of Disorders in Mineral Metabolism with Progression of Chronic Kidney Disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Role of dietary phosphorus in the progression of renal failure

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Aortic pulse wave velocity as a marker of cardiovascular risk in hypertensive patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Association between pulse pressure and mortality in patients undergoing maintenance hemodialysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Pathogenesis of vascular calcification in chronic kidney disease.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Arterial stiffening and vascular calcifications in end-stage renal disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Stiffness of capacitive and conduit arteries: prognostic significance for end-stage renal disease patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Natural history of vascular calcification in dialysis and transplant patients.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Association of serum phosphate with vascular and valvular calcification in moderate CKD.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Serum phosphorus levels associate with coronary atherosclerosis in young adults

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Vascular calcification mechanisms

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Vascular calcification in chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Association between Chronic Kidney Disease and Coronary Artery Calcification: The Dallas Heart Study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Vascular calcification and cardiovascular function in chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Phosphorus and uremic serum up-regulate osteopontin expression in vascular smooth muscle cells

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Phosphate regulation of vascular smooth muscle cell calcification

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Uremia induces the osteoblast differentiation factor Cbfa1 in human blood vessels.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

The emerging role of phosphate in vascular calcification

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

The mechanism of phosphorus as a cardiovascular risk factor in CKD

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Phosphate feeding induces arterial medial calcification in uremic mice: role of serum phosphorus, fibroblast growth factor-23, and osteopontin

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Clinical epidemiology of cardiovascular disease in chronic kidney disease prior to dialysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Impact of left ventricular hypertrophy on survival in end-stage renal disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Clinical and echocardiographic disease in patients starting end-stage renal disease therapy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Parathormon, calcium, phosphorus, and left ventricular structure and function in normotensive hemodialysis patients.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Changes in heart rate variability in chronic uremic patients during ultrafiltration and hemodialysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Adverse effects of hyperphosphatemia on myocardial hypertrophy, renal function, and bone in rats with renal failure.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Effects of short daily versus conventional hemodialysis on left ventricular hypertrophy and inflammatory markers: a prospective, controlled study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Left ventricular hypertrophy: is hyperphosphatemia among dialysis patients a risk factor?

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass and quality of life: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Adenosine triphosphate turnover in humans. Decreased degradation during relative hyperphosphatemia

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Circadian rhythms of blood minerals in humans

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Serum concentration of 1,25-dihydroxyvitamin D in the human: diurnal variation

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Endocrine functions of bone in mineral metabolism regulation.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Latest findings in phosphate homeostasis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

FGF23 is processed by proprotein convertases but not by PHEX.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

FGF23, PHEX, and MEPE regulation of phosphate homeostasis and skeletal mineralization

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Mutation of the mouse klotho gene leads to a syndrome resembling ageing

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Klotho converts canonical FGF receptor into a specific receptor for FGF23

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Circulating FGF-23 is regulated by 1alpha,25-dihydroxyvitamin D3 and phosphorus in vivo

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Human fibroblast growth factor-23 mutants suppress Na+-dependent phosphate co-transport activity and 1alpha,25-dihydroxyvitamin D3 production

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

The autosomal dominant hypophosphatemic rickets R176Q mutation in fibroblast growth factor 23 resists proteolytic cleavage and enhances in vivo biological potency

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Dietary phosphorus regulates serum fibroblast growth factor-23 concentrations in healthy men.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Effect of acute changes of serum phosphate on fibroblast growth factor (FGF)23 levels in humans

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Effects of gonadal steroid withdrawal on serum phosphate and FGF-23 levels in men

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Evidence for a signaling axis by which intestinal phosphate rapidly modulates renal phosphate reabsorption

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Central control of renal sodium-phosphate (NaPi-2) transporters.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

FGF-23 is elevated by chronic hyperphosphatemia

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Postprandial mineral metabolism and secondary hyperparathyroidism in early CKD

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Vitamin D insufficiency and deficiency in chronic kidney disease. A single center observational study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Acute effect of oral phosphate loading on serum fibroblast growth factor 23 levels in healthy men

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Pathogenesis of secondary hyperparathyroidism

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Current understanding of the molecular actions of vitamin D.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Metabolic acidosis suppresses 25-hydroxyvitamin in D3-1alpha-hydroxylase in the rat kidney. Distinct site and mechanism of action

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Prevalence of calcidiol deficiency in CKD: a cross-sectional study across latitudes in the United States

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Parathyroid hormone fragments inhibit active hormone and hypocalcemia-induced 1,25(OH)2D synthesis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Effect of daily oral vitamin D and calcium therapy, hypophosphatemia, and endogenous 1-25 dihydroxycholecalciferol on parathyroid hormone and phosphate wasting in renal transplant recipients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Post-transplant hypophosphatemia: Tertiary 'Hyper-Phosphatoninism'?

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Tertiary 'hyperphosphatoninism' accentuates hypophosphatemia and suppresses calcitriol levels in renal transplant recipients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Activated injectable vitamin D and hemodialysis survival: a historical cohort study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: a longitudinal study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

The vitamin D deficiency pandemic and consequences for nonskeletal health: mechanisms of action.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Fibroblast growth factor 23: a possible cause of left ventricular hypertrophy in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Cardiac hypertrophy in vitamin D receptor knockout mice: role of the systemic and cardiac renin-angiotensin systems

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Mineral metabolism and arterial functions in end-stage renal disease: potential role of 25-hydroxyvitamin D deficiency

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Fibroblast Growth Factor 23 (FGF23) Predicts Progression of Chronic Kidney Disease: The Mild to Moderate Kidney Disease (MMKD) Study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Poly[allylamine hydrochloride] (RenaGel): a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Calcium acetate control of serum phosphorus in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. The RenaGel Study Group

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: a secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Phosphorus binders and survival on hemodialysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Effect of manipulating serum phosphorus with phosphate binder on circulating PTH and FGF23 in renal failure rats

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Sevelamer hydrochloride and calcium bicarbonate reduce serum fibroblast growth factor 23 levels in dialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Effect of food additives on hyperphosphatemia among patients with end-stage renal disease: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Salivary phosphate-binding chewing gum reduces hyperphosphatemia in dialysis patients.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Effects of intensive glucose lowering in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Registered Dietitian Time Requirements in the Modification of Diet in Renal Disease Study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Is controlling phosphorus by decreasing dietary protein intake beneficial or harmful in persons with chronic kidney disease?

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Lanthanum carbonate reduces phosphorus burden in patients with CKD stages 3 and 4: a randomized trial

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.246

7 January 2021

Identifiers

DOI

10.1038/KI.2009.246

1 reference

21 August 2017

1 reference

PubMed ID

19606082